Similarly, several reports have shown that dual PI3K/mTOR inhibitors used as monotherapies mainly lead to cytostatic antitumor effects in lung cancer and other cancers [17, 34], such as pancreatic cancer. The gene discussed is PIK3CA; the disease is lung carcinoma.